The role of pembrolizumab in the treatment of recurrent malignant pleural mesothelioma - case report

06/2019

MUDr. Daniel Krejčí; MUDr. Jana Krejčí; MUDr. Petr Opálka, CSc.; doc. MUDr. Norbert Pauk, Ph.D.

Klinika pneumologie 3. LF UK a Nemocnice Na Bulovce, Praha

SUMMARY

Malignant mesothelioma belongs to a group of rare tumors and is feared due to the short survival period and limited therapeutic options. Presented case report summarizes the diagnosis and treatment of a patient with extensive malignant mesothelioma, documenting significant late response to the first line standard therapy, and particularly the considerable effect of pembrolizumab in the second line treatment after progression.

Key words

mesothelioma, pembrolizumab